50 results about "Tumour immunotherapy" patented technology

The present invention is in the field of immunotherapy, in particular tumor immunotherapy. The present invention provides pharmaceutical formulations for delivering RNA to antigen presenting cells such as dendrite cells (DCs) in the spleen after systemic administration. In particular, the formulations described herein enable to induce an immune response after systemic administration of antigen-coding RNA.

The invention belongs to the technical field of biopharming, and specifically relates to a novel chimeric antigen receptor (CAR) targeting CD19 and applications thereof. The chimeric antigen receptorincludes signal peptide, nanoantibodies targeting CD19, a transmembrane region, costimulatory factors and an intracellular signal domain; and the intracellular signal domain is the mutant CD3[zeta] intracellular signal domain. Through the using of the nanoantibodies targeting CD19 and the mutant CD3[zeta] intracellular signal domain, the molecular weight of the chimeric antigen receptor can be reduced, convenient nucleic acid transfection and molecular biology operation can be achieved, antineoplastic activity can be enhanced, stronger tumor killing effects can be achieved, and therefore, novel approaches can be provided for the development of a novel tumor immunotherapy; and the chimeric antigen receptor can be used in CAR-T therapy, and shows good application prospects.

The invention provides a fusion protein comprising a flagellin adjuvant and a tumor antigen. Also provided are compositions comprising a flagellin adjuvant and a tumor antigen. The invention also provides pharmaceutical formulations for inducing an immune response against tumor antigen and methods thereof, and a method for treating tumor in tester.

The invention provides a construction method of an immune cell tumor killing capacity detection model. The construction method comprises the following steps: (1) 24 after egg membranes of embryos of zebrafish fertilized for 24-96 hours are removed, injecting tumor cells labeled by a first living cell staining agent into zebrafish bodies, then executing culturing in culture water containing a melanin inhibitor, and screening out the zebrafish with the tail parts labeled by the first living cell staining agent; (2) after the collected zebrafish is anesthetized, the zebrafish is divided into an immune cell injection group and a control group, injecting immune cells labeled by a second living cell staining agent into the immune cell injection group in a microinjection mode, injecting a carriersolution into the control group, and then putting the zebrafish in the culture water containing the melanin inhibitor for continuous culture. Short period, time saving, labor saving and low modelingcost are achieved by adopting the construction method, and a constructed detection model can accurately and objectively evaluate the effect of tumor immunotherapy. The invention also provides a detection model prepared based on the method and application thereof.

A tumor or a malignant disease can be treated by the combined administration of mesenchymal stem cells (MSCs) with an anti-tumor immunotherapy. The MSCs need not be genetically modified, and do not include exogenous nucleic acids that encode immune response-stimulating cytokines. The anti-tumor immunotherapy can be a cellular immunotherapy, such as administration of chimeric antigen receptor (CAR) T cells, in which the T cell receptor binds specifically to a tumor-associated antigen.

The invention provides a gingseng extract product FQR1 as well as a preparation and an application thereof, and provides a FQR1 induced culture method for DC-CIK cell. The method comprises the following steps: a collection of peripheral blood, an acquisition of tumor antigens, a separation of mononuclear cells, a washing, an induction of DC-CIK cells, a culture, etc. The obtained gingseng extract product FQR1 can effectively increase propagation of DC-CIK cells, improve tumor killing activity of DC-CIK cells, and prolong the survival time with tumor of tumor-bearing mice with the DC-CIK cell therapy.

Provided herein are predictive biomarker signatures that identify patients as likely to benefit from TIL therapy. Also provided are tumor immunotherapy resistance pathways that may be targets of combination therapies to enhance TIL therapy.

The invention provides a method for constructing an immune healthy synovial sarcoma xenograft mouse model; the method comprises cultivating a generation P0, to be specific, resuscitating a tumor tissue block of a synovial sarcoma patient stored in a liquid nitrogen environment, then transplanting the tumor tissue block into an immunodeficient mouse under a sterile condition, and pretreating a micewith normal immunity by cyclosporine; culturing a generation Px, to be specific, inoculating the tumor tissue block, grown in a mouse from any of the generations P0 to Px, into the mouse pretreated with cyclosporine to form a generation Px mouse; and culturing a generation Py, to be specific, inoculating a synovial sarcoma tumor tissue block, grown in a mouse from any of the generations Px to Py-1, into the mouse with normal immunity until tumor tissues grow in the mouse, so that culturing of the generation Py is completed. The invention solves the problem that the traditional PDX (patient-derived xenograft) model has no immune system, provides an in-vivo model for the research on tumor immunotherapy, and widens the application range of the PDX model.

The invention discloses a serum-free culture medium of CAR-T cells. The serum-free culture medium consists of a basic culture medium and the following components added into the culture medium: nicergoline, icariin, ferulate, IL-2, IL-15, vitamin E and L-glutamine. The nicergoline and the icariin are added into the serum-free culture medium of the CAR-T cells in the invention, so that the proliferation activity of the CAR-T cells can be effectively improved; and a large number of CAR-T cells can be harvested within a short time. The ferulate is also added, so that the number of living cells in the harvested cells is easily increased; and the cell survival rate is increased. The components, the L-2, the IL-15, the vitamin E and the L-glutamine jointly act; the proliferation activity of the CAR-T cells is improved; the used components are safe; blood components such as plasma are not added; the culture cost of the CAR-T cells is reduced; and the burden of a patient is relieved. The invention further provides a culture method of the CAR-T cells; the culture method is simple and convenient to operate and easy to implement; and popularization and application of the CAR-T cells in the field of tumour immunotherapy are facilitated.

The present invention relates to tumor immunotherapy. In particular, the present invention provides methods and compositions for converting cancer cells into antigen presenting cells. Thus the present invention provides immunogenic compositions for the treatment and prevention of cancer.

The invention discloses an intestinal flora regulator. The intestinal flora regulator comprises icarisid I. The intestinal flora regulator can regulate the structure of intestinal flora, improve the metabolism of the flora, convert the intestinal flora of a patient into a healthy intestinal flora outline, enhance the immunity of a host and resist and inhibit cancers, and can be applied to the fields of medicines, foods and the like. The invention further discloses an application of the intestinal flora regulator to increment of the content of intestinal probiotics and the content of intestinalflora secondary metabolites, and an application of the intestinal flora regulator to preparation of functional foods, anti-cancer drugs or cancer immunotherapy. The content of lactobacillus and bifidobacterium in intestinal tracts can be increased, and generation of metabolite short-chain fatty acid is promoted; the intestinal flora regulator is free from toxic or side effects, can be used for daily eating, regulates intestinal flora and improves immunity; the icariside I has a good inhibition effect on tumor cells, and can also improve the low reaction rate of a patient to tumor immunotherapy and possible side effects; and a new direction is provided for the application of the icariside I.

The invention discloses a preparation method of lipidosome containing alkannin and anthracycline chemotherapeutic drugs and an application of the lipidosome in synergistic anti-tumor immunotherapy, and belongs to the technical field of pharmaceutical preparations. Firstly, alkannin and an anthracycline drug mitoxantrone or adriamycin are simultaneously encapsulated in a liposome, a synergistic proportion is screened by using a co-loaded liposome through a cytotoxicity experiment, an uptake experiment and ICD induction capability, and the prepared dual-drug-loading liposome has a pH/GSH dual-response release characteristic, can deliver a drug to a tumor tissue, the anti-tumor effects is synergistically induced, the administration dosage of the two drugs is reduced, the toxic and side effects of the drugs are reduced, and the purposes of enhancing the effect and reducing the toxicity are achieved.

The success of anti-tumor immune responses requires effector T cells to infiltrate solid tumors, a process guided by chemokines. Herein, we demonstrate that in vivo post-translational processing of chemokines by dipeptidylpeptidase 4 (DPP4, also known as CD26) limits lymphocyte migration to sites of inflammation and tumors. Inhibition of DPP4 enzymatic activity enhanced tumor rejection by preserving biologically active CXCL10, and increasing trafficking into the tumor by lymphocytes expressing the counter-receptor CXCR3. Furthermore, DPP4 inhibition improved adjuvant-based immunotherapy, adoptive T cell transfer and checkpoint blockade. These findings provide the first direct in vivo evidence for controlling lymphocyte trafficking through CXCL10 cleavage and support the use of DPP4 inhibitors for stabilizing the biologically active form of chemokines as a strategy to enhance tumor immunotherapy.

The invention discloses a cytoplasmic polyadenylation element-binding protein 4 vaccine, and preparation and application thereof. The vaccine is a ISCOM-DNA compound, the preparation method of the vaccine comprises: cloning of full-length DNA of cytoplasmic polyadenylation element-binding protein 4, cloning of full-length DNA of tumor necrosis factor BAFF, construction of a recombinant vector pStar-CPEB4/BAFF, construction of a pStar-CPEB4/BAFF engineering bacteria, inducible expression of CPEB4, and preparation of the ISCOM-DAN compound. The vaccine has good application prospect on neuroglioma controlling. The vaccine has the advantages of being efficient, low in toxicity, simple in preparation method and the like, and is applicable to medicines for tumour immunotherapy.

Provided is a tumor antigen protein, gene, or peptides derived from topoisomerase 2 alpha. As it is discovered that topoisomerase 2 alpha binds to an MHC class I or II antigen, thereby forming a complex, and the complex is recognized by cytotoxic T lymphocytes, the tumor antigen can be used in tumor immunotherapy.